Company profilePharmaceutical#12 of 1,318 in Pakistan✓ No DRAP alerts

Barrett Hodgson Pakistan (Private) Ltd.

Pharmaceutical company · 402 brands · 336 molecules

Ranked #1 of 23 companies in Eye Conditions

402 registered products 94 pharmaceutical brands 336 distinct molecules 0 DRAP alerts

Company overview

402
registered products
94
pharmaceutical brands
336
distinct molecules
12
therapeutic classes
0
DRAP alerts

Barrett Hodgson Pakistan (Private) Ltd. is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 402 product registrations across 336 distinct molecules. It is the 12th largest registrant in Pakistan by product count, and ranks 1st of 23 in Eye Conditions. Its portfolio is concentrated in Eye Conditions and Anti-Infectives. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by Barrett

433 products matched in our catalogue · showing 80 — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

175
ceilings with an approval date
0
not revised in 2+ years
2025
oldest approval year
202520
2026155

Top molecules by brand count

Eye39 brands
Ciprofloxacin15 brands
Prednisolone10 brands
Lignocaine10 brands
Paracetamol9 brands
Fluconazole7 brands
Artemether7 brands

Therapeutic classes

Eye Conditions · 28Anti-Infectives · 20Cardiac Care · 18Other Beta-Lactam, Cephalosporins & Penems · 11Pain Management · 11Gastro · 9Neuro · 8Angiotensin-Ii Antagonists, Combinations · 7Antiinflammatory And Antirheumatic Products · 7Blood Conditions · 7Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 6Anti-Infective, Ophthalmologicals · 6

Conditions treated

General Infections · 17Allergy/Infections · 12Hypertension · 11Glaucoma/Mydriasis · 8Dry Eye/Allergy · 5Oral Agents · 5Pain Killers · 5Ulcer/Reflux/Flatulence/Acidity · 4High Cholestrol · 4Anaemia · 4Anxiety/Depression/Insomnia · 4PAIN · 3

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official309 products · Rs 30.11 – Rs 17,235.87
DVAGO169 products · Rs 31 – Rs 4,355.75
Servaid229 products · Rs 38.35 – Rs 2,140
Median across source: Rs 266

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

Atco Pharma International (Pvt) Ltd holds 165 molecules not in this portfolio
AcyclovirAdapaleneAdapleneAlbuterolAminophyllineAmlodipine 6.95Mg Amlodipine Base
GETZ PHARMA PAKISTAN (PVT) LTD. holds 193 molecules not in this portfolio
),Formoterol3 ) 20Mg} Folic AcidAcetazolamideAcyclovirAdrenalineAlbendazole
NABIQASIM INDUSTRIES (PVT) LTD. holds 133 molecules not in this portfolio
2 MiuAcefyllin PiperazineAcefyllineAcetaminophinAcetylsalicyclic AcidAcyclovir

Get the full profile for Barrett

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.